POST Online Media Lite Edition


Sanofi appoints Paul Hudson as chief executive officer

Christian Fernsby |
Paris, France - Sanofi, a pharmaceutical company, appointed Paul Hudson as chief executive officer of the group.

Article continues below

Mr. Hudson is a seasoned leader with a strong international experience, particularly in the United States, Japan and Europe.

Mr. Hudson spent his 28-years career with major pharmaceutical companies such as Schering Plough, Astra Zeneca and Novartis.

Mr. Hudson has been CEO of Novartis Pharmaceuticals since 2016.

He is a member of the Executive Committee of Novartis.

Mr. Hudson joined Novartis from AstraZeneca PLC, where he most recently was president, AstraZeneca United States and executive vice president, North America.

He also served as representative director and president of AstraZeneca K.K. in Japan; as president of AstraZeneca’s business in Spain; and as vice president and primary care director, United Kingdom.

Before joining AstraZeneca in 2006, Mr. Hudson held roles of increasing responsibility at Schering-Plough, including leading biologics global marketing.

He began his career in sales and marketing roles at GlaxoSmithKline UK and Sanofi-Synthélabo UK.

Mr. Hudson holds a degree in economics from Manchester Metropolitan University (MMU) in the UK and a diploma in marketing from the Chartered Institute of Marketing in the UK.

In 2018, Mr. Hudson was awarded an honorary doctorate in business administration from MMU.


Kering appoints three new directors to board
SouthBridge Group appoints Frannie Léautier as senior partner
Renault fires CEO Thierry Bolloré
Dazzl appoints APO Group CEO Lionel Reina to company board
Laredo Petroleum appoints Frances Powell Hawes as independent director

What to read next

Sanofi plans 670 job cuts in France
Sanofi charged with FCPA violations
Sanofi Q2 IFRS earnings per share fell 25.6 percent